Valuation: Supernus Pharmaceuticals, Inc.

Market Cap 279.81Cr 244.58Cr 226.19Cr 207.56Cr 392.83Cr 27TCr 399.65Cr 2.7TCr 1.06TCr 13TCr 1.05TCr 1.03TCr 45TCr P/E 2026 *
108x
P/E 2027 * 32.2x
Enterprise Value 279.81Cr 244.58Cr 226.19Cr 207.56Cr 392.83Cr 27TCr 399.65Cr 2.7TCr 1.06TCr 13TCr 1.05TCr 1.03TCr 45TCr EV / Sales 2026 *
3.23x
EV / Sales 2027 * 2.74x
Free-Float
95.54%
Yield 2026 *
-
Yield 2027 * -
1 day+1.49%
1 week+0.74%
Current month+4.97%
1 month+12.02%
3 months-5.00%
6 months-2.01%
Current year-1.77%
1 week 46.09
Extreme 46.09
49.06
1 month 43.54
Extreme 43.54
51.37
Current year 42.45
Extreme 42.45
59.68
1 year 32.2
Extreme 32.2
59.68
3 years 21.99
Extreme 21.99
59.68
5 years 21.99
Extreme 21.99
59.68
10 years 13.12
Extreme 13.12
61.25
Manager TitleAgeSince
Chief Executive Officer 64 22/12/2005
Director of Finance/CFO 67 23/08/2021
Chief Tech/Sci/R&D Officer 54 01/01/2017
Director TitleAgeSince
Director/Board Member 65 23/03/2015
Chairman 81 10/08/2016
Director/Board Member 80 16/11/2010
Date Insider Type Main position Quantity % Market Cap.
16/03/26 Fiscal year

Chief Technology Officer

3,21,750 0.5738%
13/03/26 Others

Founder

60,000 0.1070%
12/03/26 Sell

Director

5,369 0.0096%
Change 5-day change 1-year change 3-year change Capi.($)
+1.48%+0.74%+45.34%+65.89% 279.81Cr
+2.91%+5.95%+60.56%+23.98% 32TCr
-1.99%-3.22%+21.20%-9.14% 6.86TCr
+0.25%+2.36%+34.94%+93.69% 919.73Cr
+0.34%-0.73%+6.41%+0.09% 852.47Cr
-3.05%+0.42%+6.92%+28.13% 404.28Cr
+1.53%-1.00%-18.56%+3.79% 419.78Cr
+1.87%+5.04%-37.18%+24.94% 356.42Cr
-0.81%+7.81%+12.16%-16.29% 225.77Cr
-3.46%+13.29%-11.84%+40.22% 200.61Cr
Average -0.09%+0.37%+12.00%+25.53% 4.2TCr
Weighted average by Cap. +1.88%-1.70%+49.64%+19.61%

Financials

2026 *2027 *
Net sales 87Cr 76Cr 70Cr 64Cr 121.74Cr 8.36TCr 123.86Cr 836Cr 328.41Cr 4.08TCr 325.66Cr 318.51Cr 14TCr 102.29Cr 89Cr 83Cr 76Cr 143.6Cr 9.86TCr 146.1Cr 986.11Cr 387.38Cr 4.81TCr 384.14Cr 375.7Cr 17TCr
Net income 2.59Cr 2.27Cr 2.1Cr 1.92Cr 3.64Cr 249.8Cr 3.7Cr 25Cr 9.82Cr 121.99Cr 9.74Cr 9.52Cr 421.15Cr 9.3Cr 8.13Cr 7.52Cr 6.9Cr 13Cr 896.09Cr 13Cr 90Cr 35Cr 437.59Cr 35Cr 34Cr 1.51TCr
Net Debt - -
Logo Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.
Employees
778
Date Price Change Volume
17/26/17 $48.89 +1.41% 62,751
16/26/16 $48.21 +1.01% 5,93,351
15/26/15 $47.73 +2.29% 5,00,546
14/26/14 $46.66 -1.46% 8,24,025
13/26/13 $47.35 -2.29% 6,85,279
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
48.21USD
Average target price
63.50USD
Spread / Average Target
+31.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SUPN Stock